Lifeint and the First Affiliated Hospital of Xiamen University announced a strategic collaboration to explore the use of platelet-based TCPseq technology in early lung cancer detection. The announcement identified the Xiamen Lujie Thoracic Oncology Research Institute as the proposed collaboration and translation platform, with the aim of supporting clinical research and auxiliary diagnosis.
The original announcement described the First Affiliated Hospital of Xiamen University as a tertiary general hospital providing healthcare, teaching, research, prevention and rehabilitation. It described the hospital as the largest in southwestern Fujian and reported that it was the first in the province to achieve HIMSS EMRAM Stage 7 and the first large general hospital in China to hold both that rating and JCI academic medical center accreditation.
The Xiamen Lujie Thoracic Oncology Research Institute was established by the hospital’s thoracic surgery department as a nonprofit research organization. Its stated work includes thoracic oncology research, genotyping, prevention education and exploration of cancer prevention and treatment approaches.
The historical announcement described Lifeint as a high-tech enterprise based in Xiamen’s Haicang Biomedical Industrial Park, with investment from a fund affiliated with the Ministry of Science and Technology. It described a team including doctoral, overseas-trained and international researchers, with technical advisers from the Thousand Talents Program. It reported progress in platelet RNA sequencing and machine-learning liquid biopsy research, and a first prize in the Xiamen division of the fifth China Innovation and Entrepreneurship Competition.
The announcement described TCPseq as combining low-input amplification, next-generation sequencing of platelet RNA, and machine-learning approaches combining single features with multiple classifiers or multiple features with a single classifier. It reported a 60,000-gene expression profile and a positive accuracy above 90% in the lung cancer samples studied, without providing the underlying cohort or performance definition on this page. These historical figures are not evidence of current clinical performance; the publication and validation data should be consulted before clinical interpretation. The announcement also described plans to expand the sample set, including stage 0, I and II lung cancer samples, and improve the analysis.
